Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Small cell lung cancer is a highly malignant tumor, and its first-line treatment has not
broken through platinum-containing dual-drug chemotherapy in the past 30 years. Because small
cell lung cancer has the characteristics of easy resistance after first-line chemotherapy,
increased difficulty in treatment after resistance, and poor efficacy of second-line
treatment, how to formulate a plan that can control tumor progression to the greatest extent
has become a hot issue in recent research. Recently, immunotherapy and targeted therapy have
made breakthrough progress in small cell lung cancer, but its efficacy still needs to be
further improved. As immune combined chemotherapy combined with targeted therapy first
achieved good results in other tumors, this study aims to explore a longer disease-free
survival time and higher overall survival rate of patients with small cell lung cancer
through immunotherapy combined with targeted therapy combined with chemotherapy. Program to
bring new hope to patients. At the same time, this study will evaluate the safety of the
program, explore the prognostic indicators that may exist in the treatment, and provide new
inspiration for subsequent patient selection.